Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/12—Antidiarrhoeals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/36—Opioid-abuse
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
  • C07K5/126—Tetrapeptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/64—Cyclic peptides containing only normal peptide links
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
  • G01N33/9486—Analgesics, e.g. opiates, aspirine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
  • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
  • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
  • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2500/00—Screening for compounds of potential therapeutic value
  • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Definitions

• the present invention relates to peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and chronic pain.
• Activation of the mu opioid receptor is among the most effective means of alleviating a wide range of pain conditions.
• opioid receptors e.g., mu (3,19,20), delta (6,9), and kappa (12-14)
• the vast majority of clinically used opioids act at the mu receptor.
• the absence of the mu receptor eliminates the analgesic effects of morphine (8), illustrating its central role in opioid-induced pain relief.
• mu agonists can be attributed to several factors, including their presence in numerous regions of the nervous system that regulate pain processing and activation of multiple mechanisms that limit pain transmission (e.g., inhibiting release of excitatory transmitters from the peripheral nervous system and decreasing cellular excitability in the central nervous system).
• a lead compound from this group reportedly was 3 -fold more potent than morphine in alleviating neuropathic pain and showed reduced rewarding properties in animal models that are correlated with abuse potential. While these results are promising, the development of additional compounds showing equal or better properties is desirable.
• the instant invention addresses this need by providing peptide analogs having unexpectedly better solubility and side-effect profiles than the previously described materials.
• An embodiment of the instant invention is directed to pentapeptide and hexapeptide analogs of endomorphins that differ from the previously described tetrapeptide analogs by having (i) a carboxy-terminal extension with an amidated hydrophilic amino acid, (ii) a substitution in amino acid position 2; or (iii) a combination of (i) and (ii).
• the pentapeptide and hexapeptide analogs of the present invention exhibit increased solubility relative to the tetrapeptides while maintaining favorable therapeutic ratios of analgesia-to-side effects.
• the compounds of the present invention are cyclic peptides that act as mu opioid receptor agonists with high affinity. These compounds provide relief of acute pain, chronic pain, or both, and comprise or consist of compounds of Formula I:
• Xi and X 4 each independently is an acidic amino acid (i.e., an amino acid comprising a carboxylic acid-substituted side-chain) or a basic amino acid (i.e., an amino acid comprising an amino-substituted side-chain), with the proviso that if Xi is an acidic amino acid (e.g., D-Asp or D-Glu), then X 4 is a basic amino acid (e.g., Lys, Orn, Dpr, or Dab), and vice versa.
• an acidic amino acid i.e., an amino acid comprising a carboxylic acid-substituted side-chain
• a basic amino acid i.e., an amino acid comprising an amino-substituted side-chain
• Xi is D-Asp, D-Glu, D-Lys, D-Orn, D-Dpr or D-Dab; while X 4 preferably is Asp, Glu, Lys, Orn, Dpr or Dab.
• X 2 andX 3 each independently is an aromatic amino acid (i.e., an amino acid comprising an aromatic group in the side chain thereof).
• X 2 preferably is Trp, Phe, or N-alkyl-Phe, where the alkyl group preferably comprises 1 to about 6 carbon atoms, i.e., a (Ci to C 6 ) alkyl group.
• X 3 preferably is Phe, D-Phe, or p-Y-Phe where Y is N0 2 , F, CI, or Br.
• X 5 is selected from the group consisting of -NHR, Ala-NHR, Arg- NHR, Asn-NHR, Asp-NHR, Cys-NHR, Glu-NHR, Gln-NHR, Gly-NHR, His-NHR, Ile-NHR, Leu-NHR, Met-NHR, Orn-NHR, Phe -NHR, Pro-NHR, Ser-NHR, Thr-NHR, Trp-NHR, Tyr- NHR and Val-NHR; where R is H or an alkyl group (e.g.
• a (Ci to Cio) alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, or isoheptyl).
• the peptide of Formula I is cyclic (shown as "c[Xi-X 2 -X 3 -X 4 ]" in the formula) by virtue of an amide linkage between the carboxylic acid and amino substituents of the side chains of amino acid residues Xi and X 4 .
• the linkage can be an amide bond formed between the side chain amino group of the D-Lys, D-Orn, D-Dpr, D-Dab, Lys, Orn, Dpr, or Dab with the side chain carboxyl group of D-Asp, D-Glu, Asp, or Glu.
• X 5 is NHR, R is H, and X 5 can be -NH 2 (i.e., the peptide is an amidated pentapeptide), or Ala-NH 2 , Arg-NH 2 , Asn-NH 2 , Asp-NH 2 , Cys-NH 2 , Glu-NH 2 , Gln-NH 2 , Gly-NH 2 , His-NH 2 , Ile-NH 2 , Leu-NH 2 , Met- NH 2 , Orn-NH 2 , Phe-NH 2 , Pro-NH 2 , Ser-NH 2 , Thr-NH 2 , Trp-NH 2 , Tyr-NH 2 , or Val-NH 2 , (i.e., the peptide is an amidated hexapeptide).
• X 5 is NH 2 .
• X 5 is Ala-NH 2 , Arg-NH 2 , Asn-NH 2 , Asp-NH 2 , Cys-NH 2 , Glu-NH 2 , Gln- NH 2 , Gly-NH 2 , His-NH 2 , Ile-NH 2 , Leu-NH 2 , Met-NH 2 , Orn-NH 2 , Phe-NH 2 , Pro-NH 2 , Ser-NH 2 , Thr-NH 2 , Trp-NH 2 , Tyr-NH 2 , or Val-NH 2 .
• Another embodiment of the invention is directed to a peptide of Formula I, wherein Xi is D-Asp, D-Glu, D-Lys, or D-Orn; and X 4 is Asp, Glu, Lys, or Orn.
• Another embodiment of the invention is directed to a compound of Formula I, wherein X 5 is NHR and R is a (Ci to Cio) alkyl.
• Another embodiment of the invention is directed to a peptide of Formula I, wherein the aromatic amino acid of X 2 is Trp, Phe, or N-alkyl-Phe, and the alkyl group of N-alkyl-Phe is a
• X 2 is N-methyl-Phe (N-Me-Phe).
• Another embodiment of the invention is directed to a peptide of Formula I, wherein the aromatic amino acid residue of either X 2 or X 3 is Phe, D-Phe, Trp, D-Trp, D-Tyr, N-alkyl-Phe, and the alkyl group of N-alkyl-Phe is (Ci to C 10 ) alkyl or p-Y-Phe, wherein Y is N0 2 , F, CI, or
• Another embodiment of the invention is directed to a peptide of Formula I, wherein the aromatic amino acid of X 3 is Phe, D-Phe, or p-Y-Phe, wherein Y is N0 2 , F, CI, or Br.
• X 3 is p-Cl-Phe.
• Another embodiment of the invention is directed to a peptide of Formula I selected from the group consisting of:
• Another aspect of the invention is directed to a pharmaceutical composition
• a pharmaceutical composition comprising a peptide of Formula I and a pharmaceutically acceptable carrier (e.g., a diluent or excipient).
• a pharmaceutically acceptable carrier e.g., a diluent or excipient
• Yet another aspect of the invention is directed to the use of a peptide of Formula I in a method of treating a patient having a condition that responds to an opioid, or a condition for which opioid treatment is standard in the art.
• a method comprises or consists of administering to the patient an effective amount of a peptide of Formula I of the invention.
• Particular embodiments of this method can be followed for the purpose of providing at least one effect selected from (i) analgesia (pain relief), (ii) relief from a gastrointestinal disorder such as diarrhea, (iii) therapy for an opioid drug dependence, and (iv) treatment of any condition for which an opioid is indicated.
• the peptides of Formula I can be used to treat acute or chronic pain.
• Uses for the peptides of Formula I also include, but are not be limited to, use as antimigraine agents, immunomodulatory agents, immunosuppressive agents or antiarthritic agents.
• Certain embodiments of the methods of the present invention such as treatment of pain or opioid drug dependence, are directed to patients having a history of opioid substance abuse.
• the peptide is administered parenterally (e.g., intravenous).
• This invention also relates to a peptide of Formula I for use in one of said methods of treatment.
• Another aspect of the invention is directed to a method of activating or regulating a mu- opioid receptor by contacting the mu-opioid receptor with a compound of the invention, as well as the use of the peptide of Formula I in such a treatment.
• Another aspect of the invention is directed to a method of measuring the quantity of a mu opioid receptor in a sample using a peptide of Formula I.
• This method can comprise or consist of the following steps: (i) contacting a sample suspected of containing a mu opioid receptor with a peptide of Formula I to form a compound-receptor complex, (ii) detecting the complex, and (iii) quantifying the amount of complex formed.
• Another aspect of the invention is directed to the use of a peptide of Formula I to perform a competitive assay method of detecting the presence of a molecule that binds to a mu opioid receptor.
• This method can comprise or consist of the following steps: (i) contacting a sample suspected of containing a molecule that binds to a mu opioid receptor with a mu opioid receptor and a peptide of Formula I, wherein the compound and receptor form a compound-receptor complex; (ii) measuring the amount of the complex formed in step (i); and (iii) comparing the amount of complex measured in step (ii) with the amount of a complex formed between the mu opioid receptor and the peptide in the absence of said sample.
• FIG. 1 shows Tyr-c[D-Lys-Trp-Phe-Glu]-NH 2 (SEQ ID NO: l), which is described as "Compound 1" in the following disclosure.
• the structural and basic molecular formulae, as well as the molecular weight (MW), are shown for Compound 1.
• FIG. 2 shows Tyr-c[D-Glu-Phe-Phe-Lys]-NH 2 (SEQ ID NO:2), which is described as "Compound 2" in the following disclosure.
• the structural and basic molecular formulae, as well as the molecular weight (MW) are shown for Compound 2.
• FIG. 3 shows Tyr-c[D-Glu-Phe-Phe-Lys]-Gly-NH 2 (SEQ ID NO:4), which is described as "Compound 4" in the following disclosure.
• the structural and basic molecular formulae, as well as the molecular weight (MW), are shown for Compound 4.
• FIG. 4 shows opioid receptor binding activity for Compound 1.
• A mu receptor binding of "Compound 1" (triangles) or DAMGO (squares).
• B Antagonist activity of Compound 1 against binding of SNC80 to delta receptor.
• FIG. 5 shows effects of compounds on antinociception and respiration.
• B Effects of Compounds 1 and 2 on respiratory minute volume (MV) over a 20-minute period as compared to morphine. * p ⁇ 0.05. *** p ⁇ 0.001.
• FIG. 6 shows the effects of Compound 2 on antinociception and motor impairment.
• B The bar graph shows the ratio of the area under the curve (AUC) for percent motor impairment relative to the AUC for percent antinociception. This ratio is significantly greater (*p ⁇ 0.05) for morphine than for Compound 2, consistent with greater motor impairment relative to analgesia for morphine.
• FIG. 8 shows a graph of paw pressure required to elicit a paw withdrawal response at times before and after spared nerve injury surgery for rats treated with Compound 2, compared to rats treated with morphine or no analgesic.
• Peptides of Formula I which are cyclic pentapeptide and hexapeptide analogs of endomorphin-1 (Tyr-Pro-Trp-Phe-NH 2 , SEQ ID NO: 8) and endomorphin-2 (Tyr-Pro-Phe-Phe- NH 2 , SEQ ID NO:9) were prepared.
• Non-limiting examples of peptides with the composition of Formula I include Compounds 1-7 below, wherein the side chains of amino acid residues 2 (Xi) and 5 (X 4 ) in the sequence are linked by an amide bond between the side-chains thereof.
• the formulae of Compounds 1-7 are shown in Table 1.
• the peptides of Formula I includes peptides with an N-alkylated phenylalanine in position 3 (X 2 ).
• Alkyl groups suitable in the peptides of the present invention include (Ci to C 10 ) alkyl groups, preferably (Ci to C 6 ) alkyl groups (e.g., methyl or ethyl).
• Compound 6 illustrates a cyclic analog whose linear primary amino acid sequence contains an N- methylated phenylalanine in position 3.
• peptides of this invention include compounds wherein the amino acid at position 4 (X 3 ) is p-Y-phenylalanine, wherein Y is N0 2 , F, CI or Br, in order to enhance receptor binding and potency.
• Compounds 1 ( Figure 1), 2 ( Figure 2), 5 and 6 are examples of cyclic pentapeptides
• Compounds 3, 4 ( Figure 3) and 7 are examples of cyclic hexapeptides of the instant invention.
• amino acids described herein include alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gin), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (He), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), valine (Val), ornithine (Orn), naphthylalanine (Nal),
• Chemicals (incorporated herein by reference in its entirety, particularly those sections therein listing amino acid derivatives and unnatural amino acids) can be used in preparing compounds of the invention.
• Xi can be, for example, D-Asp, D-Glu, D-Lys, D-Orn, D-Dpr or D-Dab
• X 4 can be, for example, Asp, Glu, Lys, Orn, Dpr or Dab.
• an amino acid or derivative thereof can be used as Xi or X 4 if it contains either an amino group or a carboxyl group in its side chain.
• the amino acid used for Xi can be a D- enantiomeric form of such amino acid.
• X 2 and X 3 in Formula I are aromatic amino acids.
• aromatic amino acids are unsubstituted or substituted aromatic amino acids selected from the group consisting of phenylalanine, heteroarylalanine, naphthylalanine (Nal), homophenylalanine, histidine, tryptophan, tyrosine, arylglycine, heteroarylglycine, thyroxine, aryl-beta-alanine, and heteroaryl- beta-alanine.
• substituted versions of these aromatic amino acids are disclosed in U.S. Patent No. 7,629,319, which is herein incorporated by reference in its entirety.
• aromatic amino acid refers to an a-amino acid comprising an aromatic group (including aromatic hydrocarbon and aromatic heterocyclic groups) in the side-chain thereof.
• X 2 in Formula I can be N-alkyl-Phe, where the alkyl group comprises 1 to about 6 carbon atoms. Alternatively, the alkyl group can comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbons, for example.
• the alkyl group can be a methyl (i.e., X 2 is N-Me- Phe), ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, or isoheptyl group, or any other branched form thereof, for example.
• X 2 is N-Me- Phe
• ethyl propyl
• isopropyl butyl, isobutyl
• pentyl isopentyl
• hexyl isohexyl
• heptyl isoheptyl group
• This alpha amino group is involved in an amide bond with the Xi residue in certain peptides of the invention; therefore, the alpha amino group of X 2 (when N-alkyl-Phe) as it exists in such peptides is a tertiary amide.
• X 3 in Formula I is para-Y-Phe (p-Y-Phe), where Y is N0 2 , F, CI, or Br, for example.
• Y is N0 2 , F, CI, or Br
• X 3 can be p-Cl-Phe.
• the N0 2 , F, CI, or Br groups can be linked in the ortho or meta positions of the phenyl ring of Phe.
• Any aromatic amino acid incorporated in the compounds of the invention such as at X 2 or X 3 can have the above groups linked thereto in the ortho, meta, or para positions.
• the solubility of the peptides of Formula I typically is enhanced relative to the prior art tetrapeptide analogs of the endomorphins.
• Compound 1 was soluble in water, saline and 20% PEG/saline at about 43, 21 and 90 mg/mL, respectively, compared to less than about 2 mg/mL for the previously described compounds. While increases in solubility are associated with improved pharmaceutical delivery properties, higher solubility is also often associated with reduced functional activity (e.g., receptor binding) that may depend on lipophilicity.
• the peptides of Formula I can be prepared by conventional solution phase (2) or solid phase (18) methods with the use of proper protecting groups and coupling agents; references 2 and 20 are herein incorporated by reference in their entirety. Such methods generally utilize various protecting groups on the various amino acid residues of the peptides. A suitable deprotection method is employed to remove specified or all of the protecting groups, including splitting off the resin if solid phase synthesis is applied.
• the peptides can be synthesized, for example, as described below.
• Peptides of Formula I were synthesized on Rink Amide resin via Fmoc chemistry. A t- butyl group was used for Tyr, Glu, Asp side chain protection and Boc was used for Lys, Orn and Trp side chain protection. All materials were obtained from EMD Biosciences, Inc (San Diego, CA). The peptide was assembled on Rink Amide resin by repetitive removal of the Fmoc protecting group and coupling of protected amino acid.
• HBTU (0-benzotriazole-N,N,N',N'- tetramethyluronium hexafluorophosphate; CAS # 94790-37-1) and HOBT (N- hydroxybenzotriazole; CAS # 2592-95-2) were used as coupling reagents in N,N- dimethylformamide (DMF) and diisopropylethylamme (DIPEA) was used as a base.
• DMF N,N- dimethylformamide
• DIPEA diisopropylethylamme
• the resin was treated with an aqueous cocktail of trifluoroacetic acid and triisopropylsilane (TFA/TIS/H 2 0 cocktail) for cleavage and removal of the side chain protecting groups. Crude peptide was precipitated with diethyl ether and collected by filtration.
• VYDAC® 218TP510 column 250 x 10 mm; Alltech Associates, Inc.
• solvent B solvent A
• 20-25% B over a period of 30 minutes
• 25-80% B over a period of 1 minute
• isocratic elution over 9 minutes at a flow rate of about 4 mL/min
• absorptions being measured at both 214 and 280 nm.
• the same gradient was used for analytical runs on a VYDAC®218TP54 column (250 x 4.6 mm) at a flow rate of about 1 mL/min.
• the instant invention also provides pharmaceutical preparations which contain a pharmaceutically effective amount of the peptides in a pharmaceutically acceptable carrier (e.g., a diluent, complexing agent, additive, excipient, adjuvant and the like).
• a pharmaceutically acceptable carrier e.g., a diluent, complexing agent, additive, excipient, adjuvant and the like.
• the peptide can be present for example in a salt form, a micro-crystal form, a nano-crystal form, a co-crystal form, a nanoparticle form, a mirocparticle form, or an amphiphilic form.
• the carrier can be an organic or inorganic carrier that is suitable for external, enteral or parenteral applications.
• the peptides of the present invention can be compounded, for example, with the usual non-toxic,
• Non- limiting examples of carriers that can be used include water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, liquid or aerosol form.
• carriers include water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, liquid or aerosol form.
• stabilizing, thickening and coloring agents and perfumes can be used.
• the present invention also provides pharmaceutical compositions useful for treating pain and related conditions, as described herein.
• the pharmaceutical compositions comprise at least one peptide of Formula I in combination with a pharmaceutically acceptable carrier, vehicle, or diluent, such as an aqueous buffer at a physiologically acceptable pH (e.g., pH 7 to 8.5), a polymer-based nanoparticle vehicle, a liposome, and the like.
• a pharmaceutically acceptable carrier such as an aqueous buffer at a physiologically acceptable pH (e.g., pH 7 to 8.5), a polymer-based nanoparticle vehicle, a liposome, and the like.
• the pharmaceutical compositions can be delivered in any suitable dosage form, such as a liquid, gel, solid, cream, or paste dosage form.
• the compositions can be adapted to give sustained release of the peptide.
• the pharmaceutical compositions include, but are not limited to, those forms suitable for oral, rectal, nasal, topical, (including buccal and sublingual),
• parenteral including intramuscular, subcutaneous, and intravenous
• spinal epidural, intrathecal
• central intracerebroventricular
• the compositions can, where appropriate, be conveniently provided in discrete dosage units.
• the pharmaceutical compositions of the invention can be prepared by any of the methods well known in the pharmaceutical arts. Some preferred modes of administration include intravenous (iv), topical, subcutaneous, oral and spinal.
• compositions suitable for oral administration include capsules, cachets, or tablets, each containing a predetermined amount of one or more of the peptides, as a powder or granules.
• the oral composition is a solution, a suspension, or an emulsion.
• the peptides can be provided as a bolus, electuary, or paste.
• Tablets and capsules for oral administration can contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, colorants, flavoring agents, preservatives, or wetting agents.
• the tablets can be coated according to methods well known in the art, if desired.
• Oral liquid preparations include, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs.
• the compositions can be provided as a dry product for constitution with water or another suitable vehicle before use.
• Such liquid preparations can contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and the like.
• the additives, excipients, and the like typically will be included in the compositions for oral administration within a range of concentrations suitable for their intended use or function in the composition, and which are well known in the pharmaceutical formulation art.
• peptides of the present invention will be included in the compositions within a therapeutically useful and effective concentration range, as determined by routine methods that are well known in the medical and pharmaceutical arts.
• a typical composition can include one or more of the peptides at a concentration in the range of at least about 0.01 nanomolar to about 1 molar, preferably at least about 1 nanomolar to about 100 millimolar.
• compositions for parenteral, spinal, or central administration e.g. by bolus injection or continuous infusion
• injection into amniotic fluid can be provided in unit dose form in ampoules, pre-filled syringes, small volume infusion, or in multi-dose containers, and preferably include an added preservative.
• the compositions for parenteral administration can be suspensions, solutions, or emulsions, and can contain excipients such as suspending agents, stabilizing agents, and dispersing agents.
• the peptides can be provided in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
• a suitable vehicle e.g. sterile, pyrogen-free water
• a typical composition can include one or more of the peptides at a concentration in the range of at least about 0.01 nanomolar to about 100 millimolar, preferably at least about 1 nanomolar to about 10 millimolar.
• compositions for topical administration of the peptides to the epidermis can be formulated as ointments, creams, lotions, gels, or as a transdermal patch.
• transdermal patches can contain penetration enhancers such as linalool, carvacrol, thymol, citral, menthol, t-anethole, and the like.
• Ointments and creams can, for example, include an aqueous or oily base with the addition of suitable thickening agents, gelling agents, colorants, and the like.
• Lotions and creams can include an aqueous or oily base and typically also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, coloring agents, and the like.
• Gels preferably include an aqueous carrier base and include a gelling agent such as cross-linked polyacrylic acid polymer, a derivatized polysaccharide (e.g., carboxymethyl cellulose), and the like.
• the additives, excipients, and the like typically will be included in the compositions for topical administration to the epidermis within a range of concentrations suitable for their intended use or function in the composition, and which are well known in the pharmaceutical formulation art.
• peptides of the present invention will be included in the compositions within a therapeutically useful and effective concentration range, as determined by routine methods that are well known in the medical and pharmaceutical arts.
• a typical composition can include one or more of the peptides at a concentration in the range of at least about 0.01 nanomolar to about 1 molar, preferably at least about 1 nanomolar to about 100 millimolar.
• compositions suitable for topical administration in the mouth include lozenges comprising the peptide in a flavored base, such as sucrose, acacia, or tragacanth; pastilles comprising the peptide in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
• the pharmaceutical compositions for topical administration in the mouth can include penetration enhancing agents, if desired.
• the additives, excipients, and the like typically will be included in the compositions of topical oral administration within a range of concentrations suitable for their intended use or function in the composition, and which are well known in the pharmaceutical formulation art.
• peptides of the present invention will be included in the compositions within a therapeutically useful and effective concentration range, as determined by routine methods that are well known in the medical and pharmaceutical arts.
• a typical composition can include one or more of the peptides at a concentration in the range of at least about 0.01 nanomolar to about 1 molar, preferably at least about 1 nanomolar to about 100 millimolar.
• a pharmaceutical composition suitable for rectal administration comprises a peptide of the present invention in combination with a solid or semisolid (e.g., cream or paste) carrier or vehicle.
• a solid or semisolid carrier or vehicle e.g., cream or paste
• rectal compositions can be provided as unit dose suppositories.
• Suitable carriers or vehicles include cocoa butter and other materials commonly used in the art.
• the additives, excipients, and the like typically will be included in the compositions of rectal administration within a range of concentrations suitable for their intended use or function in the composition, and which are well known in the pharmaceutical formulation art.
• the peptides of the present invention will be included in the compositions within a therapeutically useful and effective concentration range, as determined by routine methods that are well known in the medical and pharmaceutical arts.
• a typical composition can include one or more of the peptides at a concentration in the range of at least about 0.01 nanomolar to about 1 molar, preferably at least about 1 nanomolar to about 100 millimolar.
• compositions of the present invention suitable for vaginal administration are provided as pessaries, tampons, creams, gels, pastes, foams, or sprays containing a peptide of the invention in combination with carriers as are known in the art.
• compositions suitable for vaginal administration can be delivered in a liquid or solid dosage form.
• the additives, excipients, and the like typically will be included in the compositions of vaginal administration within a range of concentrations suitable for their intended use or function in the composition, and which are well known in the pharmaceutical formulation art.
• the peptides of the present invention will be included in the compositions within a therapeutically useful and effective concentration range, as determined by routine methods that are well known in the medical and pharmaceutical arts.
• a typical composition can include one or more of the peptides at a concentration in the range of at least about 0.01 nanomolar to about 1 molar, preferably at least about 1 nanomolar to about 100 millimolar.
• compositions suitable for intra-nasal administration are also encompassed by the present invention.
• Such intra-nasal compositions comprise a peptide of the invention in a vehicle and suitable administration device to deliver a liquid spray, dispersible powder, or drops.
• Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilizing agents, or suspending agents.
• Liquid sprays are conveniently delivered from a pressurized pack, an insufflator, a nebulizer, or other convenient means of delivering an aerosol comprising the peptide.
• Pressurized packs comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas as is well known in the art. Aerosol dosages can be controlled by providing a valve to deliver a metered amount of the peptide.
• pharmaceutical compositions for administration by inhalation or insufflation can be provided in the form of a dry powder composition, for example, a powder mix of the peptide and a suitable powder base such as lactose or starch.
• Such powder composition can be provided in unit dosage form, for example, in capsules, cartridges, gelatin packs, or blister packs, from which the powder can be administered with the aid of an inhalator or insufflator.
• the additives, excipients, and the like typically will be included in the compositions of intra-nasal administration within a range of concentrations suitable for their intended use or function in the composition, and which are well known in the pharmaceutical formulation art.
• the peptides of the present invention will be included in the compositions within a therapeutically useful and effective concentration range, as determined by routine methods that are well known in the medical and pharmaceutical arts.
• a typical composition can include one or more of the peptides at a concentration in the range of at least about 0.01 nanomolar to about 1 molar, preferably at least about 1 nanomolar to about 100 millimolar.
• the pharmaceutical compositions of the present invention can include one or more other therapeutic agent, e.g., as a combination therapy.
• the additional therapeutic agent will be included in the compositions within a therapeutically useful and effective concentration range, as determined by routine methods that are well known in the medical and pharmaceutical arts.
• the concentration of any particular additional therapeutic agent may be in the same range as is typical for use of that agent as a monotherapy, or the concentration may be lower than a typical monotherapy concentration if there is a synergy when combined with a peptide of the present invention.
• the present invention provides for the use of the peptides of Formula I for treatment of pain, treatment of discomfort associated with gastrointestinal disorders, and treatment of drug dependence.
• Methods for providing analgesia (alleviating or reducing pain), relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence in patients, such as mammals, including humans, comprise administering to a patient suffering from one of the aforementioned conditions an effective amount of a peptide of Formula I.
• Diarrhea may be caused by a number of sources, such as infectious disease, cholera, or an effect or side- effect of various drugs or therapies, including those used for cancer therapy.
• the peptide is administered parenterally or enterally.
• the dosage of the effective amount of the peptides can vary depending upon the age and condition of each individual patient to be treated. However, suitable unit dosages typically range from about 0.01 to about 100 mg. For example, a unit dose can be in the range of about 0.2 mg to about 50 mg. Such a unit dose can be administered more than once a day, e.g., two or three times a day.
• All of the embodiments of the peptides of Formula I can be in the "isolated" state.
• an "isolated" peptide is one that has been completely or partially purified.
• the isolated compound will be part of a greater composition, buffer system or reagent mix.
• the isolated peptide may be purified to homogeneity.
• composition may comprise the peptide or compound at a level of at least about 50, 80, 90, or 95% (on a molar basis or weight basis) of all the other species that are also present therein.
• Mixtures of the peptides of Formula I may be used in practicing methods provided by the invention.
• Additional embodiments of the current invention are directed towards methods of using the peptides of Formula I disclosed herein in medicinal formulations or as therapeutic agents, for example. These methods may involve the use of a single peptide, or multiple peptides in combination (i.e., a mixture). Accordingly, certain embodiments of the invention are drawn to medicaments comprising the peptides of Formula I, and methods of manufacturing such medicaments.
• the terms “reducing,” “inhibiting,” “blocking,” “preventing”, alleviating,” or “relieving” when referring to a compound mean that the compound brings down the occurrence, severity, size, volume, or associated symptoms of a condition, event, or activity by at least about 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 22.5%, 25%, 27.5%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, or 100% compared to how the condition, event, or activity would normally exist without application of the compound or a composition comprising the compound.
• the terms “increasing,” “elevating,” “enhancing,” “upregulating”, “improving,” or “activating” when referring to a compound mean that the compound increases the occurrence or activity of a condition, event, or activity by at least about 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 22.5%, 25%, 27.5%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 400%, 500%, 750%, or 1000% compared to how the condition, event, or activity would normally exist without application of the compound or a composition comprising the compound. [0058] The following examples are included to demonstrate certain aspects of the invention.
• Example 1 Binding and activation of human opioid receptors.
• the peptides of Formula I showed surprisingly high affinity (subnanomolar) for the human mu opioid receptor with selective binding relative to the delta and kappa opioid receptors.
• the compounds were tested in standard binding assays using 3 H-DAMGO (tritiated [D-Ala 2 , N- Me-Phe 4 , Gly-ol]-enkephalin; CAS # 78123-71-4), 3 H-DPDPE (CAS# 88373-73-3), and 3 H- U69593 (CAS# 96744-75-1) to label mu, delta and kappa receptors, respectively, in membranes from CHO cells expressing human cloned receptors.
• 3 H-DAMGO tritiated [D-Ala 2 , N- Me-Phe 4 , Gly-ol]-enkephalin; CAS # 78123-71-4
• 3 H-DPDPE CAS# 88373-73-3
• 3 H- U69593 CAS# 96744-75-
• endomorphin-1 (EMI, SEQ ID NO:8) and endomorphin -2 (EM2, SEQ ID NO:9) are the most selective endogenous mu agonists previously reported. Analogs based on these natural opioids show greater affinity for the mu receptor, albeit with less selectivity. Tetrapeptide endomorphin analogs described earlier (U.S. Patent No. 5,885,958; ckl, Tyr-c[D-Lys-Trp-Phe] (SEQ ID NO: 10); ck2, Tyr-c[D-Lys-Phe-Phe] (SEQ ID NO: 11)) showed the highest affinity of the compounds tested. Peptides of Formula I, which include a hydrophilic amino acid and amidated carboxy-terminus (Compounds 1, 2, 5) retained high affinity binding, but increased selectivity for the mu receptor.
• Table 2 Compound binding to opioid receptors.
• Receptor activation GTPyS functional assay. Functional activation of the three opioid receptors was tested in standard assays in which the non-hydrolysable GTP analog, 35 S- GTPyS, was used to quantify activation of cloned human opioid receptors expressed in cell membranes.
• Figure 4A shows that Compound 1 is a full efficacy agonist with significantly greater potency than the reference compound, DAMGO.
• Figure 4B shows that Compound 1 exhibits unexpected full efficacy as a delta antagonist; i.e., it is able to inhibit the delta activation produced by an ED 80 dose of the reference delta agonist, SNC80 (CAS # 156727-74-1).
• Table 3 shows that all agonists tested are potent activators of the mu receptor, with EC50 (median effective concentration) values at low-nanomolar to sub-nanomolar concentrations. All compounds were found to be full efficacy (>90%) agonists at the mu receptor.
• the endomorphins and the compounds of Formula I of the invention show remarkable selectivity for receptor activation, with delta activation below 50% at concentrations up to 10 ⁇ , reflecting selectivity > 100000.
• Compounds 1 and 3 showed full efficacy delta antagonism; Compound 1 exhibited this antagonism at a relatively low concentration.
• Beta-arrestin recruitment is an intracellular protein that is recruited to the mu opioid receptor following activation by agonists. It has been shown to activate intracellular signaling pathways that in many cases are independent of well- known G-protein mediated pathways. It has recently been shown that beta-arrestin knockout mice exhibit altered responses to morphine, including increased analgesia and decreased side effects such as tolerance, respiratory depression, and constipation (16). These results indicate that the analgesic and side-effects of morphine are separable by manipulation of cell signaling processes. These findings also provide support for the recent concept known variously as "functional selectivity”, “biased agonism”,”agonist directed signaling” and other descriptions.
• agonists capable of producing a different cascade of signaling at a given receptor could produce a different profile of desired and undesired effects relative to other agonists for that receptor.
• Three of the analogs of this invention were tested and showed patterns of beta-arrestin recruitment (ranging from high potency with low efficacy to moderate potency with significant efficacy) that were different from each other and from morphine.
• beta arrestin results suggest that these compounds exhibit "functional selectivity", favoring analgesia over adverse side-effects.
• delta antagonism is expected to attenuate opioid- induced tolerance, dependence, and reward. As first shown in 1991 (1) and supported in numerous studies since, delta antagonists can reduce morphine-induced tolerance and
• Example 2 Providing analgesia of greater duration, but with reduced respiratory depression, relative to morphine after intravenous administration.
• Respiratory depression is a major safety issue in the use of opioids.
• Effectiveness after systemic administration, such as intravenous (i.v.) injection, is unusual for peptide -based compounds, and would be critical for the clinical utility thereof.
• Two peptides (Compounds 1 and 2) were tested for their effects on respiration (minute ventilation) and duration of antinociception relative to morphine. Rats with indwelling jugular catheters were placed in a BUXCOTM whole body plethysmograph apparatus for determining multiple respiratory parameters. For 20 minutes following i.v.
• Example 3 Providing analgesia of greater duration than morphine with reduced impairment of neuromotor coordination and cognitive function.
• Neuromotor and cognitive impairment are characteristics of opioids that are of particular importance in two populations, i.e., military combat troops, where escape from immediate danger can require unimpaired motor and cognitive skills, and the elderly, where these impairments can exacerbate compromised function including impaired balance, which can lead to increased risk of fractures.
• Example 3a Neuromotor coordination.
• FIG. 6A illustrates that Compound 2 produces significantly greater antinociception, but significantly reduced motor impairment, relative to morphine (MS). Both compounds were administered by cumulative intravenous (i.v.) doses in rats. Increasing quarter-log doses were given every 20 minutes, and a tail flick (TF) test (a test of latency to remove the tail from a hot light beam) followed by a rotorod test were conducted about 15 minutes after each injection. Escalating doses were given until each animal showed greater than 90% maximum possible effect (%MPE) on the TF test, determined as: [(latency to TF minus baseline latency) / (9 sec maximum (cut off) time to avoid tissue damage) minus baseline)] x 100.
• TF tail flick
• %Maximum Possible Inhibition (%MPI) of motor coordination was determined as 100 - (latency to fall/180 x 100).
• Example 3b Cognitive impairment.
• a widely used standard test of cognitive function is the Morris Water Maze (MWM).
• MMM Morris Water Maze
• rats learn to find a hidden escape platform based on spatial memory. Average latency to the platform, as well as average distance from the platform (a measure unaffected by swim speed), decrease as the task is acquired and provide indices of spatial memory.
• an injection of morphine produced impairment of spatial memory, as reflected by a significant increase in the latency to, and average distance from, the platform.
• Compound 2 at doses that provide equal or greater antinociception than morphine, did not produce significant impairment.
• animals are first allowed, on Day 1, to freely explore a 3 -compartment apparatus consisting of a small "start box” and two larger compartments that are perceptually distinct (gray vs. black and white stripes in this example).
• the animals are given an i.v. injection of drug and confined to one compartment, and vehicle is given in the other.
• the time at which the drug or vehicle is given (a.m. or p.m.) is counterbalanced, as is the compartment in which the drug is given (preferred or non-preferred, as determined during the baseline test).
• This unbiased design allows for detection of both drug preference and drug aversion.
• Kieffer B. L. Befort K., Gaveriaux-Ruff C. and Hirth C. G. (1992) The ⁇ -opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci U. S A 89, 12048-12052; (10) Kuehn B. M. (2009) New pain guideline for older patients: avoid NSAIDs, consider opioids. JAMA 302, 19;

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Biomedical Technology (AREA)
• Immunology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Gastroenterology & Hepatology (AREA)
• Epidemiology (AREA)
• Pain & Pain Management (AREA)
• Addiction (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Microbiology (AREA)
• Food Science & Technology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Cell Biology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Biotechnology (AREA)
• Emergency Medicine (AREA)
• Toxicology (AREA)

Priority Applications (17)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=45441820

Family Applications (1)

Country Status (13)

Cited By (8)

Families Citing this family (5)

Family Cites Families (6)

• 2011
  • 2011-07-08 PL PL11804387T patent/PL2590992T3/pl unknown
  • 2011-07-08 SI SI201131226T patent/SI2590992T1/sl unknown
  • 2011-07-08 EP EP17167969.9A patent/EP3246333B1/en not_active Not-in-force
  • 2011-07-08 JP JP2013519718A patent/JP6039553B2/ja not_active Expired - Fee Related
  • 2011-07-08 HU HUE11804387A patent/HUE033875T2/en unknown
  • 2011-07-08 HR HRP20171119TT patent/HRP20171119T1/hr unknown
  • 2011-07-08 WO PCT/US2011/043306 patent/WO2012006497A2/en not_active Ceased
  • 2011-07-08 ES ES11804387.6T patent/ES2632787T3/es active Active
  • 2011-07-08 CA CA2810170A patent/CA2810170C/en not_active Expired - Fee Related
  • 2011-07-08 RS RS20170643A patent/RS56129B1/sr unknown
  • 2011-07-08 EP EP11804387.6A patent/EP2590992B1/en not_active Not-in-force
  • 2011-07-08 PT PT118043876T patent/PT2590992T/pt unknown
• 2012
  • 2012-05-22 US US13/477,423 patent/US8716436B2/en active Active
• 2014
  • 2014-05-02 US US14/268,057 patent/US20150315238A1/en not_active Abandoned
• 2016
  • 2016-01-21 JP JP2016010055A patent/JP6279626B2/ja not_active Expired - Fee Related
• 2017
  • 2017-07-03 CY CY171100700T patent/CY1120618T1/el unknown
  • 2017-09-14 US US15/704,730 patent/US20180222940A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events